Minimal residual disease

Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting

Retrieved on: 
Saturday, December 9, 2023
Senior, NGS, Neoplasm, PB, MRD, FDA, Jan Vansina, Bone marrow, Mantle cell lymphoma, Blood, Multiple myeloma, Health, MD, Society, ADPT, Minimal residual disease, ASH, University, Non-Hodgkin lymphoma, Abstract, DNA sequencing, Associate professor, Genetics, Meeting, Assistant, OS, PFS, Public health, MCL, Pharmaceutical industry

The data are being presented in more than 30 abstracts at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12 in San Diego, California.

Key Points: 
  • The data are being presented in more than 30 abstracts at the 65th Annual Meeting of the American Society of Hematology (ASH), December 9-12 in San Diego, California.
  • “The already-substantial body of evidence supporting clonoSEQ’s prognostic value and clinical actionability is expanding in several important ways at ASH this year,” said Susan Bobulsky, Senior Vice President, Diagnostics, Adaptive Biotechnologies.
  • At this timepoint, MRD status from both PB and BM were similarly prognostic of patients’ progression-free survival (PFS).
  • 88% (15/17) of patients that were MRD negative at day 28 remained MRD negative at 6 months.

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

Retrieved on: 
Tuesday, December 5, 2023
Sequence, ASCT, Skylark (rocket), NGS, MRD, Relapse, Durability, Haematopoietic system, Rituximab, Bortezomib, Minimal residual disease, CLL, ATLAS, Allotransplantation, B-ALL

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Key Points: 
  • Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
    Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study
    Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study
    Impact of Sequence Uniqueness on MRD Monitoring in NGS Immunoglobulin Sequencing: An Analysis of Ig Loci Among >1200 Diffuse Large B-Cell Lymphoma Patients Tested By ClonoSEQ
    Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort
    Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)
    Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
    Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy
    A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
    Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
    Final Analysis of a Phase 2 Trial of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma (NDMM) without Autologous Stem Cell Transplantation (ASCT)
    Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Update for the "Watch" Registry, a Real-World Observational Study Using clonoSEQ® to Monitor MRD in Lymphoid Malignancies

Prenetics Announces Second Quarter 2023 Financial Results

Retrieved on: 
Friday, September 15, 2023
ACT, Minimal residual disease, MRD, Clinical trial, EBITDA, Partnership, Investment, Genomics, Rare-earth element, Pharmaceutical industry

HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates.

Key Points: 
  • HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates.
  • Prenetics provided US$100m in consideration, with US$80m in cash and US$20m of shares in Prenetics.
  • ACT Genomics is expected to launch a 500-gene panel and a 100-gene panel comprehensive genomic profiling “liquid” biopsy test by the fourth quarter of 2023.
  • Significant improvement in operational efficiency and cost optimization, reducing adjusted EBITDA from continuing operations from a loss of US$(9.8) million in the first quarter of 2023 to US$(5.3) million in the current quarter with further reductions expected in the second half of 2023.

Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell

Retrieved on: 
Friday, September 8, 2023
LSE, DNA, Methylation, Minimal residual disease, Lung cancer, Lung, MRD, Patient, Neoplasm, Recurrence, Potential, Medical imaging, NSCLC

GUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal Residual Disease (MRD) product, CanCatch® (PROPHETTM panel), was enrolled in a prospective observational study (MEDAL, MEthylation based Dynamic Analysis for Lung cancer, NCT03634826).

Key Points: 
  • GUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal Residual Disease (MRD) product, CanCatch® (PROPHETTM panel), was enrolled in a prospective observational study (MEDAL, MEthylation based Dynamic Analysis for Lung cancer, NCT03634826).
  • The MEDAL is a 5-year study that aimed to investigate the clinical utility of MRD in patients with non-small cell lung cancer (NSCLC) with various approaches to ctDNA detection, including MEDAL-Methylation and MEDAL-PROPHET (a novel Patient-specific pROgnostic and Potential tHErapeutic marker Tracking).
  • In MEDAL-PROPHET study, the CanCatch® demonstrated superior performance in head-to-head comparisons with tumor-agnostic fixed-panel and tumor-informed fixed-panel MRD assays.
  • [1] Chen et al., Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer, Cancer Cell (2023), https://doi.org/10.1016/j.ccell.2023.08.010 .

Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

Retrieved on: 
Friday, June 2, 2023
Survival rate, Partnership, IVDR, CSO, Genomics, NGS, Survival, Bone marrow, Complete Genomics, Research, Acute myeloid leukemia, MRD, AML, RUO, Patient, Laboratory, Blood, SAN, FLT3, IVD, Growth, FDA, Minimal residual disease, PCR, Medical device, Vaccine

SAN DIEGO and SAN JOSE, Calif., June 2, 2023 /PRNewswire/ -- Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics' NGS platforms.

Key Points: 
  • SAN DIEGO and SAN JOSE, Calif., June 2, 2023 /PRNewswire/ -- Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics' NGS platforms.
  • The territory is worldwide, and the field is oncology and cancer research.
  • Under the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software.
  • "We are thrilled to be partnering with Invivoscribe, a proven developer of high-quality tests to deliver a complete workflow solution," Yongwei Zhang, CEO of Complete Genomics.

Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

Retrieved on: 
Friday, June 2, 2023
Survival rate, Partnership, IVDR, CSO, Genomics, NGS, Survival, Bone marrow, Complete Genomics, Research, Acute myeloid leukemia, MRD, AML, RUO, Patient, Laboratory, Blood, SAN, FLT3, IVD, Growth, FDA, Minimal residual disease, PCR, Medical device, Vaccine

SAN DIEGO and SAN JOSE, Calif., June 2, 2023 /PRNewswire/ -- Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics' NGS platforms.

Key Points: 
  • SAN DIEGO and SAN JOSE, Calif., June 2, 2023 /PRNewswire/ -- Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics' NGS platforms.
  • The territory is worldwide, and the field is oncology and cancer research.
  • Under the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software.
  • "We are thrilled to be partnering with Invivoscribe, a proven developer of high-quality tests to deliver a complete workflow solution," Yongwei Zhang, CEO of Complete Genomics.

Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

Retrieved on: 
Monday, May 22, 2023
Minimal residual disease, MRD, Patient, CML, Chronic myelogenous leukemia, History, Medical imaging, HAVEN

While many labs only monitor previously detected mutations for analysis of Minimal Residual Disease Status (MRD) for CML patients, utilization of the HemeScreen BCR-ABL1 Panel enabled Precipio’s clinical lab to detect a co-expression of both p190 and p210 isoforms in this patient leading to more informed care decisions for the treating physician.

Key Points: 
  • While many labs only monitor previously detected mutations for analysis of Minimal Residual Disease Status (MRD) for CML patients, utilization of the HemeScreen BCR-ABL1 Panel enabled Precipio’s clinical lab to detect a co-expression of both p190 and p210 isoforms in this patient leading to more informed care decisions for the treating physician.
  • Changes in isoform expression may happen over time during the course of treatment.
  • The HemeScreen BCR-ABL1 panel simultaneously detects 4 isoforms including p190, p203, p210, and p230 to provide a comprehensive, easy to use assay for its clinical lab.
  • “We, and our customers, continue to see the benefits of using the HemeScreen BCR-ABL1 panel both in lab operations efficiencies and results such as these that enable doctors to make more informed care decisions.”

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023

Retrieved on: 
Wednesday, May 17, 2023
Biotechnology, Hospitals, Health, Pharmaceutical, Oncology, TNBC, Neoadjuvant therapy, Triple-negative breast cancer, CT, Minimal residual disease, Metastasis, Safety, Efficacy, MBC, Metastatic breast cancer, Sacituzumab govitecan, NSCLC, Line, DOM, ZIM, NAT, EC, Medical imaging, Patient

ASCENT-05/Optimice-RD (AFT-65): Phase 3, Randomized, Open-Label Study of Adjuvant Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) vs. Pembro ± Capecitabine (Cape) in Patients (Pts) with Triple-Negative Breast Cancer (TNBC) and Residual Disease after Neoadjuvant Therapy (NAT) and Surgery

Key Points: 
  • ASCENT-05/Optimice-RD (AFT-65): Phase 3, Randomized, Open-Label Study of Adjuvant Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) vs. Pembro ± Capecitabine (Cape) in Patients (Pts) with Triple-Negative Breast Cancer (TNBC) and Residual Disease after Neoadjuvant Therapy (NAT) and Surgery
    Real-World Clinical Outcomes in Patients (Pts) with HR+/HER2- Metastatic Breast Cancer (mBC) Treated with Chemotherapy (CT) in the U.S.
  • Real-World Outcomes in Patients (Pts) with Metastatic Triple-Negative Breast Cancer (mTNBC) Treated with Sacituzumab Govitecan (SG) in 2L+ in the U.S.
    ARC-7: Randomized Phase 2 Study of Domvanalimab + Zimberelimab +/- Etrumadenant vs Zimberelimab in First-Line, Metastatic, PD-L1-High Non-Small Cell Lung Cancer (NSCLC)
    VELOCITY-Lung: A Phase (Ph) 2 Study Evaluating Safety and Efficacy of Domvanalimab (Dom) + Zimberelimab (Zim) + Sacituzumab Govitecan (SG), or Etrumadenant (Etruma) + Dom + Zim, or Etruma + Zim in Patients (Pts) with Treatment-Naïve Metastatic Non-Small Cell Lung Cancer (mNSCLC)
    STAR-121: A Phase 3, Randomized Study of Domvanalimab (DOM) and Zimberelimab (ZIM) in Combination with Chemotherapy vs. Pembrolizumab (Pembro) and Chemotherapy in Patients with Untreated Metastatic Non-Small Cell Lung Cancer (mNSCLC) with No Actionable Gene Alterations
    ARC-10: A phase 3 Study to Evaluate Zimberelimab + Domvanalimab vs. Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non–Small Cell Lung Cancer
    TROPiCS-03, A Phase 2 Basket Study of Sacituzumab Govitecan (SG) in Patients (Pts) with Metastatic Solid Tumors: Early Analysis in Pts with Advanced/Metastatic Endometrial Cancer (EC)

Menarini Silicon Biosystems new CELLSEARCH® data presented at AACR 2023 annual meeting highlights trailblazing contributions of liquid biopsies for cancer research

Retrieved on: 
Thursday, April 13, 2023
AACR, Liquid biopsy, Cancer, American Association for Cancer Research, MicroRNA, Prognosis, Research, Biomarker, Chinese, EVS, Silicon, Plasma, CTC, Seminal vesicles, DLL3, Patient, Blood, Artificial intelligence, Neoplasm, AI, MSB, Minimal residual disease, Deep learning, Medical imaging

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa, April 13, 2023 /PRNewswire/ -- Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies, announced today the data from two posters to be presented at the April 14-19, 2023 annual meeting of the American Association for Cancer Research (AACR). Among them, one demonstrated the benefit of an AI algorithm for automated, reliable, and reproducible CELLSEARCH® CTC identification, while the other focused on the additional information available through the parallel immunomagnetic enrichment of tumor derived extracellular vesicles and CTCs from a single blood sample.

Key Points: 
  • BOLOGNA, Italy and HUNTINGDON VALLEY, Pa, April 13, 2023 /PRNewswire/ -- Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies, announced today the data from two posters to be presented at the April 14-19, 2023 annual meeting of the American Association for Cancer Research (AACR).
  • The posters are scheduled for Monday the 17th of April between 1:30 and 5:00 PM in Session PO.CL01.16 - Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3.
  • Additional posters will be presented during the AACR 2023 annual meeting using the CellSearch® and DEPArray™ technologies.
  • Most importantly, two new biomarkers, ARV7 and DLL3, coupled to CTC enumeration, will be available, for research use, in May 2023.

Menarini Silicon Biosystems new CELLSEARCH® data presented at AACR 2023 annual meeting highlights trailblazing contributions of liquid biopsies for cancer research

Retrieved on: 
Thursday, April 13, 2023
AACR, Liquid biopsy, Cancer, American Association for Cancer Research, MicroRNA, Prognosis, Research, Biomarker, Chinese, EVS, Silicon, Plasma, CTC, Seminal vesicles, DLL3, Patient, Blood, Artificial intelligence, Neoplasm, AI, MSB, Minimal residual disease, Deep learning, Medical imaging

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., April 13, 2023 /PRNewswire/ -- Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies, announced today the data from two posters to be presented at the April 14-19, 2023 annual meeting of the American Association for Cancer Research (AACR). Among them, one demonstrated the benefit of an AI algorithm for automated, reliable, and reproducible CELLSEARCH® CTC identification, while the other focused on the additional information available through the parallel immunomagnetic enrichment of tumor derived extracellular vesicles and CTCs from a single blood sample.

Key Points: 
  • BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., April 13, 2023 /PRNewswire/ -- Menarini Silicon Biosystems (MSB), a pioneer of liquid biopsy and single cell technologies, announced today the data from two posters to be presented at the April 14-19, 2023 annual meeting of the American Association for Cancer Research (AACR).
  • The posters are scheduled for Monday the 17th of April between 1:30 and 5:00 PM in Session PO.CL01.16 - Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3.
  • Additional posters will be presented during the AACR 2023 annual meeting using the CellSearch® and DEPArray™ technologies.
  • Most importantly, two new biomarkers, ARV7 and DLL3, coupled to CTC enumeration, will be available, for research use, in May 2023.